These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 28541596)
1. Effects of ivabradine and beta-blocker therapy on dobutamine-induced ventricular arrhythmias. Mert KU; Mert GÖ; Morrad B; Tahmazov S; Mutlu F; Çavuşoglu Y Kardiol Pol; 2017; 75(8):786-793. PubMed ID: 28541596 [TBL] [Abstract][Full Text] [Related]
2. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure. Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198 [TBL] [Abstract][Full Text] [Related]
3. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure]. Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103 [TBL] [Abstract][Full Text] [Related]
4. Dobutamine effects on spontaneous variability of ventricular arrhythmias in patients with severe chronic heart failure: the Italian Multicenter Study. Puddu PE; Papalia U; Schiariti M; Usta C; Ital Heart J; 2004 Sep; 5(9):693-701. PubMed ID: 15568599 [TBL] [Abstract][Full Text] [Related]
5. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I; J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188 [TBL] [Abstract][Full Text] [Related]
6. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K; Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517 [TBL] [Abstract][Full Text] [Related]
7. Ivabradine in patients with inappropriate sinus tachycardia. Zellerhoff S; Hinterseer M; Felix Krull B; Schulze-Bahr E; Fabritz L; Breithardt G; Kirchhof P; Kääb S Naunyn Schmiedebergs Arch Pharmacol; 2010 Dec; 382(5-6):483-6. PubMed ID: 20859616 [TBL] [Abstract][Full Text] [Related]
8. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Tardif JC; O'Meara E; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K; Eur Heart J; 2011 Oct; 32(20):2507-15. PubMed ID: 21875858 [TBL] [Abstract][Full Text] [Related]
9. Limited role for ivabradine in the treatment of chronic heart failure. Cullington D; Goode KM; Cleland JG; Clark AL Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660 [TBL] [Abstract][Full Text] [Related]
10. Enoximone echocardiography: a novel test to evaluate left ventricular contractile reserve in patients with heart failure on chronic beta-blocker therapy. Ghio S; Constantin C; Raineri C; Fontana A; Klersy C; Campana C; Tavazzi L Cardiovasc Ultrasound; 2003 Sep; 1():13. PubMed ID: 14596683 [TBL] [Abstract][Full Text] [Related]
12. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index. Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495 [TBL] [Abstract][Full Text] [Related]
13. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study. Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004 [TBL] [Abstract][Full Text] [Related]
14. [The side effects and safety of the echo-dobutamine test. The experience with 373 patients]. Fetiveau R; Lanzarini L; Poli A; Diotallevi P; Mussini MF; Montemartini C; Previtali M G Ital Cardiol; 1995 Feb; 25(2):193-201. PubMed ID: 7642024 [TBL] [Abstract][Full Text] [Related]
15. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias. Xue Y; Yamada C; Aye NN; Hashimoto K Br J Pharmacol; 1998 Aug; 124(8):1712-8. PubMed ID: 9756388 [TBL] [Abstract][Full Text] [Related]
16. [Spontaneous and stimulus-induced arrhythmia behavior in dilated cardiomyopathy]. Gonska BD; Bethge KP; Kreuzer H Z Kardiol; 1987 Sep; 76(9):546-53. PubMed ID: 2447707 [TBL] [Abstract][Full Text] [Related]
17. Reversing dobutamine-induced tachycardia using ivabradine increases stroke volume with neutral effect on cardiac energetics in left ventricular post-ischaemia dysfunction. Bakkehaug JP; Naesheim T; Torgersen Engstad E; Kildal AB; Myrmel T; How OJ Acta Physiol (Oxf); 2016 Oct; 218(2):78-88. PubMed ID: 27145482 [TBL] [Abstract][Full Text] [Related]
18. Selective heart rate reduction with ivabradine slows ischaemia-induced electrophysiological changes and reduces ischaemia-reperfusion-induced ventricular arrhythmias. Ng FS; Shadi IT; Peters NS; Lyon AR J Mol Cell Cardiol; 2013 Jun; 59():67-75. PubMed ID: 23402927 [TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure. Tanimura M; Mishima T; Steinberg MI; Borzak S; Goldstein S; Sabbah HN Cardiovasc Drugs Ther; 2000 Feb; 14(1):77-82. PubMed ID: 10755204 [TBL] [Abstract][Full Text] [Related]
20. [Comparative study between dobutamine and other catecholamines in their effects on the cardiac contraction and rhythm (author's transl)]. Ueda M; Matsumura S; Matsuda S; Kawakami M; Morishige E Nihon Yakurigaku Zasshi; 1977 May; 73(4):501-16. PubMed ID: 20396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]